Pelthos Therapeutics Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

PTHS$8.90-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

	Preferred A Shares	Preferred A Shares Par	Preferred C Shares	Preferred C Shares Par	Common Shares	Par	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders’ Deficit
Balance, December 31, 2022	600,000	$60	—	$—	1,111,112	$111	$2,432,148	$(6,138,856)	$(3,706,537)
Stock-based compensation	—	—	—	—	—	—	1,733,233	—	1,733,233
Shares issued for extension of bridge loan	—	—	—	—	18,892	2	428,398	—	428,400)
Shares issued for license	—	—	—	—	384,226	38	2,225,695	—	2,225,733
Shares issued for cash	—	—	—	—	2,525,815	253	255,159	—	255,412
Shares forfeited	—	—	—	—	(133,745)	(13)	13	—	—
Net loss	—	—	—	—	—	—	—	(7,380,793)	(7,380,793)
Balance December 31, 2023	600,000	$60	—	$—	3,906,300	$391	$7,074,646	$(13,519,649)	$(6,444,552)

CHANNEL THERAPEUTICS CORP

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

Preferred A Shares · Preferred A Shares Par · Preferred C Shares · Preferred C Shares Par · Common Shares · Par · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Deficit
Balance, December 31, 2023	600,000	$60	—	$—	3,906,300	$391	$7,074,646		$(13,519,649)	$(6,444,552)
Stock-based compensation	—	—	—	—	—	—	1,455,561		—	1,455,561
Issuance cost from shares issued on extension of bridge loan	—	—	—	—	81,112	9	447,770		—	447,779
Conversion of preferred stock into Common Stock	(600,000)	(60)	—	—	499,429	50	10		—	—
Shares issued for cash in Initial Public Offering	—	—	—	—	1,100,000	110	5,971,890		—	5,972,000
Shares issued for Standby agreement	—	—	—	—	37,500	4	(4	))	—	—
Recission of common stock	—	—	—	—	(111,129)	(11)	(91,501)		—	(91,512)
Transfer of liabilities to Chromocell Corp. for Preferred stock	—	—	2,600	—	—	—	2,153,362		—	2,153,362
Conversion of notes into Common Stock	—	—	—	—	253,492	25	1,362,796		—	1,362,821
Restricted Stock Units expense	—	—	—	—	64,498	6	104,478		—	104,484
Shares issued for services					192,854	21	239,229		—	239,250
Shares issued for payment of accounts payable	—	—	—	—	10,000	1	7,338		—	7,339
Repurchase of Common Stock					(86,196)	(9)	(74,991)		—	(75,000)
Shares issued for cash under equity line of credit, net of issuance costs and for paydown on notes payable and accrued interest	—	—	—	—	155,953	16	109,736		—	109,752
Net loss	—	—	—	—	—	—	—		(7,955,338)	(7,955,338)
Balance December 31, 2024	—	$—	2,600	$—	6,103,813	$613	$18,760,320		$(21,474,987)	$(2,714,054)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.